Funding Momentum InflaRx recently closed a $150 million underwritten offering, signaling strong capital access to fund partnerships, late-stage trials, or new indications. This creates opportunities to propose co-development, licensing, or co-commercialization deals with larger pharmaceutical partners.

First-in-Class Asset Vilobelimab is a first-in-class anti-C5a monoclonal antibody with disease-modifying activity and tolerability demonstrated across multiple clinical studies, providing a compelling value proposition for pharma partners seeking novel inflammatory mechanisms through licensing or co-development.

Complementary Pipeline The company is advancing INF904, an oral C5aR inhibitor, offering a complementary mechanism to vilobelimab. This opens opportunities for combination therapies, sequential treatment strategies, or joint development across inflammatory indications with a partner.

Global Footprint Headquartered in Germany with US presence in Ann Arbor and ongoing EU operations, InflaRx's geographic footprint supports cross-border development and commercialization strategies, including potential US-market partnerships and region-specific licensing.

Partnership Readiness As a small-to-mid-size biotech focused on inflammation and with ongoing leadership changes, InflaRx presents partnering opportunities with larger biotechs for late-stage trials, indication expansion, and scalable manufacturing arrangements.